Harrow (HROW) Income from Continuing Operations (2010 - 2026)
Harrow (HROW) recorded quarterly Income from Continuing Operations of 27602000.0 in Q1 2026, down 365.48% quarter-over-quarter from 10397000.0 in Q4 2025, and down 55.24% on a YoY basis from 61669208.34 in Q1 2025.
Harrow (HROW) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Harrow's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 27602000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 55.24% year-over-year to 27602000.0; the TTM figure through Mar 2026 stood at 11190000.0 (up 48.42% YoY), while the FY2025 annual figure was 5139000.0, up 70.6% from the prior year.
- Income from Continuing Operations was 27602000.0 for Q1 2026 at Harrow, down from 10397000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 10397000.0 in Q4 2025 to a low of 27602000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 4996941.18 across 5 years, with a median of 4391000.0 in 2023.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations plunged 1223.5% in 2022, then soared 177.17% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 1055000.0 in 2022, then slumped by 967.11% to 9148000.0 in 2023, then surged by 174.08% to 6777000.0 in 2024, then surged by 53.42% to 10397000.0 in 2025, then slumped by 365.48% to 27602000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 27602000.0 (Q1 2026), 10397000.0 (Q4 2025), and 1020000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Harrow | 1.25 Bn | 1.15 Bn | 27.05 Mn | -27.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.60 Mn |
| Dec 31, 2025 | 10.40 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -9.15 Mn |
| Sep 30, 2023 | -4.39 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -6.64 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -6.24 Mn |
| Mar 31, 2022 | -2.44 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.33 Mn |
| Jun 30, 2021 | -2.48 Mn |